Company intelligence / Profile preview
Red Queen Therapeutics
Cambridge, Massachusetts, United Statesredqueentx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Phase 1 trial results for RQ-01 in COVID-19 patients showed placebo-like safety and evidence of efficacy, with accelerated viral clearance across multiple SARS-CoV-2 variants. The company plans to advance to Phase 2 study in late 2025 for immunocompromised patients.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Stapled lipopeptidesRecombinant polypeptides
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Dana-Farber Cancer InstituteBARDA (Biomedical Advanced Research and Development Authority)
Beyond the preview
Go deeper on Red Queen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Red Queen Therapeutics.